News Releases | Insmed Incorporated

Month Year

Email Alerts

Oct 16, 2025

Insmed to Present Multiple Analyses from Phase 3 ASPEN Study at the American College of Chest Physicians Annual Meeting 2025

Read more
Oct 15, 2025

Insmed to Host Third-Quarter 2025 Financial Results Conference Call on Thursday, October 30, 2025

Read more
Sep 22, 2025

Insmed to Present Multiple Abstracts at the European Respiratory Society Congress 2025

Read more
Sep 5, 2025

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Read more
Aug 21, 2025

Insmed To Present at September Investor Conferences

Read more
Aug 12, 2025

FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease

Read more
Aug 7, 2025

Insmed Reports Second-Quarter 2025 Financial Results and Provides Business Update

Read more
Jul 24, 2025

Insmed to Host Second-Quarter 2025 Financial Results Conference Call on Thursday, August 7, 2025

Read more
Jun 11, 2025

Insmed Announces Pricing of $750 Million Public Offering of Common Stock

Read more
Jun 11, 2025

Insmed Announces Proposed $650 Million Public Offering of Common Stock

Read more
Jun 10, 2025

Insmed Announces Positive Topline Results from Phase 2b Study of Treprostinil Palmitil Inhalation Powder (TPIP) as Once-Daily Therapy in Patients with Pulmonary Arterial Hypertension

Read more
Jun 4, 2025

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Read more
May 28, 2025

Insmed To Present at the 2025 Goldman Sachs Annual Global Healthcare Conference

Read more
May 21, 2025

Brensocatib Shows Consistent Efficacy and Safety Across Three Prespecified Subgroups in New Data from Landmark ASPEN Study

Read more
May 8, 2025

Insmed Reports First-Quarter 2025 Financial Results and Provides Business Update

Read more
Apr 29, 2025

Insmed To Present at the BofA Securities 2025 Health Care Conference

Read more
Apr 24, 2025

Insmed Announces Redemption of all $569.5 Million of Remaining Outstanding 0.75% Convertible Senior Notes Due 2028

Read more
Apr 23, 2025

New England Journal of Medicine Publishes Positive Results from Insmed's Pivotal Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis

Read more
Apr 23, 2025

Insmed to Host First-Quarter 2025 Financial Results Conference Call on Thursday, May 8, 2025

Read more
Mar 25, 2025

Insmed to Present 11 Abstracts from Across Its Respiratory Portfolio at the American Thoracic Society 2025 International Conference

Read more
Mar 10, 2025

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Read more
Feb 24, 2025

Insmed Announces that FDA Does Not Currently Plan to Hold Advisory Committee Meeting to Discuss New Drug Application for Brensocatib in Patients with Bronchiectasis

Read more
Feb 20, 2025

Insmed Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides Business Update

Read more
Feb 11, 2025

Insmed To Present at March 2025 Investor Conferences

Read more
Feb 10, 2025

Insmed to Host Fourth-Quarter and Full-Year 2024 Financial Results Conference Call on Thursday, February 20, 2025

Read more

Show per page

Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your email alerts.

Investor Presentation

View the latest Insmed Investor Presentation

Download

Company

Our Global Company

Patients

Current Clinical Trials

Science

Therapies

Responsibility

Responsibility in Action

Press Releases

Company

Our Global Company

Patients

Current Clinical Trials

Science

Therapies

Responsibility

Responsibility in Action

Footer